

**Clinical trial results:****A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer****Summary**

EudraCT number	2013-004698-29
Trial protocol	HU IT DE CZ GR ES RO
Global end of trial date	15 April 2016

**Results information**

Result version number	v1 (current)
This version publication date	01 September 2017
First version publication date	01 September 2017

**Trial information****Trial identification**

Sponsor protocol code	TH-CR-415
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02093962
WHO universal trial number (UTN)	-
Other trial identifiers	IND: 121080

Notes:

**Sponsors**

Sponsor organisation name	Threshold Pharmaceuticals, Inc.
Sponsor organisation address	170 Harbor Way Ste 300, South San Francisco, California, United States, 94080
Public contact	Kristen Quigley Vice President, Clinical Operations, Threshold Pharmaceuticals, Inc., +1 650 455-9622, kquigley@thresholdpharm.com
Scientific contact	Tillman Pearce, MD, Chief Medical Officer, Threshold Pharmaceuticals, Inc., +1 650 491-4956, tpearce@thresholdpharm.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 April 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	15 April 2016
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Overall survival - To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo

Protection of trial subjects:

HIPAA standards, skin care kits both prophylactically and during/after administration of evofosfamide, periodic data safety monitoring board meetings.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 June 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 19
Country: Number of subjects enrolled	Romania: 35
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	Czech Republic: 6
Country: Number of subjects enrolled	Germany: 31
Country: Number of subjects enrolled	Greece: 9
Country: Number of subjects enrolled	Hungary: 60
Country: Number of subjects enrolled	Italy: 27
Country: Number of subjects enrolled	Russian Federation: 33
Country: Number of subjects enrolled	United States: 34
Worldwide total number of subjects	265
EEA total number of subjects	198

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	171
From 65 to 84 years	94
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment began June 2014 and ended December 2015.

### Pre-assignment

Screening details:

All subjects eligible for screening signed the consent prior to the performance of any non-routine procedures. Before undertaking any study-related procedure, the investigators or their designees explained the nature and purpose of the study, participation and termination conditions, and risks and benefits to the subject.

### Period 1

Period 1 title	Baseline period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

IXRS was used to ensure blinding was maintained.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	TH-302 and Pemetrexed

Arm description:

TH-302 (evofosfamide) in combination with Pemetrexed

Arm type	Experimental
Investigational medicinal product name	Evofosfamide
Investigational medicinal product code	TH-302
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Each dose of TH-302 was prepared in 5% dextrose in water (D5W) or normal saline and administered intravenously via an infusion pump. If there were concerns for possible extravasation or phlebitis, TH-302 could have been administered through a central line.

TH-302 was administered at a dose of 400 mg/m<sup>2</sup> by IV infusion over 30-60 minutes on Days 1 and 8 of each 21-day cycle.

Investigational medicinal product name	PEMETREXED
Investigational medicinal product code	
Other name	Alimta
Pharmaceutical forms	Powder for concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed was administered at a dose of 500 mg/m<sup>2</sup> by IV infusion over 10 minutes on Day 1 of each 21-day cycle. Pemetrexed infusions started approximately 2 to 4 hours after the completion of TH-302 or placebo administration.

<b>Arm title</b>	Placebo and Pemetrexed
------------------	------------------------

Arm description:

Control Arm

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was administered by IV infusion over 30-60 minutes on Days 1 and 8 of each 21-day cycle.

Investigational medicinal product name	PEMETREXED
Investigational medicinal product code	Alimta
Other name	
Pharmaceutical forms	Powder and solvent for concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed was administered at a dose of 500 mg/m<sup>2</sup> by IV infusion over 10 minutes on Day 1 of each 21-day cycle. Pemetrexed infusions started approximately 2 to 4 hours after the completion of TH-302 or placebo administration.

<b>Number of subjects in period 1</b>	TH-302 and Pemetrexed	Placebo and Pemetrexed
Started	134	131
Completed	0	0
Not completed	134	131
Consent withdrawn by subject	4	2
Death	76	81
Lost to follow-up	1	1
Sponsor decision	53	47

## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	TH-302 and Pemetrexed
Reporting group description:	TH-302 (evofosfamide) in combination with Pemetrexed
Reporting group title	Placebo and Pemetrexed
Reporting group description:	Control Arm

### Primary: overall survival

End point title	overall survival
End point description:	
End point type	Primary
End point timeframe:	Overall survival was defined as the duration from date of randomization to date of death from any cause. For subjects who were alive or lost to follow-up, this time was censored at the date of last contact.

End point values	TH-302 and Pemetrexed	Placebo and Pemetrexed		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	131		
Units: days				
median (confidence interval 95%)	279 (217 to 437)	272 (199 to 412)		

### Statistical analyses

Statistical analysis title	OS - Primary analysis
Comparison groups	TH-302 and Pemetrexed v Placebo and Pemetrexed
Number of subjects included in analysis	265
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.9115
Method	Logrank
Confidence interval level	95 %

### Secondary: Progression-free Survival

End point title	Progression-free Survival
-----------------	---------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

from randomization to disease progression or death)

<b>End point values</b>	TH-302 and Pemetrexed	Placebo and Pemetrexed		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	131		
Units: days				
median (confidence interval 95%)	137 (122 to 195)	87 (80 to 125)		

### Statistical analyses

<b>Statistical analysis title</b>	PFS - Primary analysis
Comparison groups	TH-302 and Pemetrexed v Placebo and Pemetrexed
Number of subjects included in analysis	265
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.0137
Method	Logrank

### Secondary: Response Rate (Partial Response or Better)

End point title	Response Rate (Partial Response or Better)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Best response recorded from the start of the study treatment including any post-treatment assessments.

<b>End point values</b>	TH-302 and Pemetrexed	Placebo and Pemetrexed		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	131		
Units: percentages	22	10		

## Statistical analyses

<b>Statistical analysis title</b>	Partial Response or Better - Primary analysis
Comparison groups	TH-302 and Pemetrexed v Placebo and Pemetrexed
Number of subjects included in analysis	265
Analysis specification	Post-hoc
Analysis type	equivalence
P-value	= 0.0217
Method	Mantel-Haenszel

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events (AEs) were collected from the start of the first dose of study drug until 30 days after discontinuation of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	19

### Reporting groups

Reporting group title	TH-302 and Pemetrexed
-----------------------	-----------------------

Reporting group description:

TH-302 (evofosfamide) in combination with Pemetrexed

Reporting group title	Placebo and Pemetrexed
-----------------------	------------------------

Reporting group description:

Control Arm

<b>Serious adverse events</b>	TH-302 and Pemetrexed	Placebo and Pemetrexed	
Total subjects affected by serious adverse events			
subjects affected / exposed	52 / 130 (40.00%)	72 / 130 (55.38%)	
number of deaths (all causes)	76	81	
number of deaths resulting from adverse events	11	8	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)	
occurrences causally related to treatment / all	2 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pyrexia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			

Acute respiratory distress syndrome			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	2 / 130 (1.54%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Dyspnoea			
subjects affected / exposed	2 / 130 (1.54%)	3 / 130 (2.31%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	1 / 1	
Pleural effusion			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			

subjects affected / exposed	3 / 130 (2.31%)	5 / 130 (3.85%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	2 / 2	0 / 0	
<b>Pulmonary haemorrhage</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
<b>Respiratory failure</b>			
subjects affected / exposed	4 / 130 (3.08%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	3 / 3	0 / 0	
<b>Psychiatric disorders</b>			
<b>Mental status changes</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
<b>Blood bilirubin increased</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>Overdose</b>			
subjects affected / exposed	4 / 130 (3.08%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper limb fracture</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Acute coronary syndrome</b>			

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Atrial fibrillation		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences causally related to treatment / all	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiac arrest		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0
Cardiac failure		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	1 / 1
Cardio-respiratory arrest		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiopulmonary failure		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	1 / 1
Myocardial infarction		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Sinus tachycardia		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Stress cardiomyopathy		

subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>Cerebral ischaemia</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebrovascular accident</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
<b>Coma</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
<b>Convulsion</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hemiparesis</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Polyneuropathy</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Quadriplegia</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Vocal cord paralysis</b>			

subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	7 / 130 (5.38%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	5 / 11	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Thrombocytopenia</b>			
subjects affected / exposed	3 / 130 (2.31%)	2 / 130 (1.54%)	
occurrences causally related to treatment / all	3 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Eye disorders</b>			
<b>Foreign body sensation in eyes</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Diarrhoea</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dysphagia</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastric ulcer</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal perforation</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Haematemesis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Skin necrosis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Secondary adrenocortical insufficiency			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacteraemia			

subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bronchitis</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Erysipelas</b>			
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Herpes zoster</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Influenza</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lower respiratory tract infection</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lung infection</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia</b>			
subjects affected / exposed	4 / 130 (3.08%)	2 / 130 (1.54%)	
occurrences causally related to treatment / all	3 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pulmonary sepsis</b>			

subjects affected / exposed	4 / 130 (3.08%)	2 / 130 (1.54%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory tract infection</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	1 / 1	1 / 1	
<b>Sepsis</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Septic shock</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
<b>Diabetes mellitus</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Failure to thrive</b>			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hyponatraemia</b>			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	TH-302 and Pemetrexed	Placebo and Pemetrexed	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	130 / 130 (100.00%)	130 / 130 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour associated fever			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	3	1	
Tumour pain			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Arteriosclerosis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Circulatory collapse			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Deep vein thrombosis			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	1	1	
Haematoma			
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)	
occurrences (all)	3	2	
Hypertension			
subjects affected / exposed	3 / 130 (2.31%)	3 / 130 (2.31%)	
occurrences (all)	3	8	
Hypotension			
subjects affected / exposed	3 / 130 (2.31%)	3 / 130 (2.31%)	
occurrences (all)	3	3	
Peripheral ischaemia			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Phlebitis			

subjects affected / exposed	8 / 130 (6.15%)	0 / 130 (0.00%)	
occurrences (all)	10	0	
Subclavian vein thrombosis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Varicose vein			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Venous insufficiency			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Venous thrombosis limb			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	28 / 130 (21.54%)	19 / 130 (14.62%)	
occurrences (all)	48	30	
Catheter site pain			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Chest pain			
subjects affected / exposed	3 / 130 (2.31%)	4 / 130 (3.08%)	
occurrences (all)	3	4	
Chills			
subjects affected / exposed	2 / 130 (1.54%)	4 / 130 (3.08%)	
occurrences (all)	2	4	
Extravasation			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Face oedema			
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)	
occurrences (all)	0	3	
Fatigue			

subjects affected / exposed	33 / 130 (25.38%)	25 / 130 (19.23%)
occurrences (all)	44	33
Feeling hot		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
General physical health deterioration		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Hyperthermia		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	2	1
Influenza like illness		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Infusion site erythema		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Infusion site extravasation		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	2	1
Infusion site phlebitis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Infusion site reaction		
subjects affected / exposed	3 / 130 (2.31%)	0 / 130 (0.00%)
occurrences (all)	3	0
Infusion site vesicles		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	1	1
Injection site erythema		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Injection site haematoma		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Injection site phlebitis		

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Injection site reaction		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Injection site vesicles		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Local swelling		
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)
occurrences (all)	1	3
Localised oedema		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Malaise		
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)
occurrences (all)	1	2
Medical device pain		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Mucosal dryness		
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)
occurrences (all)	0	2
Mucosal inflammation		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Non-cardiac chest pain		
subjects affected / exposed	4 / 130 (3.08%)	6 / 130 (4.62%)
occurrences (all)	5	6
Oedema		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Oedema peripheral		
subjects affected / exposed	10 / 130 (7.69%)	15 / 130 (11.54%)
occurrences (all)	11	24
Pain		

subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	2 / 130 (1.54%) 2	
Pyrexia subjects affected / exposed occurrences (all)	11 / 130 (8.46%) 15	12 / 130 (9.23%) 17	
Sensation of foreign body subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Xerosis subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Social circumstances Walking disability subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Reproductive system and breast disorders Balanoposthitis subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 4	0 / 130 (0.00%) 0	
Genital discomfort subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Genital erythema subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Genital rash subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Perineal erythema subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Pruritus genital subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Scrotal erythema			

subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Vaginal inflammation subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	1 / 130 (0.77%) 2	
Vulvovaginal burning sensation subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Respiratory, thoracic and mediastinal disorders			
Acquired diaphragmatic eventration subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Acute respiratory failure subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Bronchospasm subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Cough subjects affected / exposed occurrences (all)	8 / 130 (6.15%) 8	15 / 130 (11.54%) 22	
Dysphonia subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	3 / 130 (2.31%) 3	
Dyspnoea subjects affected / exposed occurrences (all)	19 / 130 (14.62%) 21	19 / 130 (14.62%) 23	
Dyspnoea exertional subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	2 / 130 (1.54%) 2	
Emphysema subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Epistaxis			

subjects affected / exposed	4 / 130 (3.08%)	5 / 130 (3.85%)
occurrences (all)	5	5
<b>Haemoptysis</b>		
subjects affected / exposed	1 / 130 (0.77%)	3 / 130 (2.31%)
occurrences (all)	1	3
<b>Hiccups</b>		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
<b>Nasal congestion</b>		
subjects affected / exposed	2 / 130 (1.54%)	1 / 130 (0.77%)
occurrences (all)	3	1
<b>Nasal dryness</b>		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
<b>Oropharyngeal pain</b>		
subjects affected / exposed	6 / 130 (4.62%)	6 / 130 (4.62%)
occurrences (all)	9	7
<b>Orthopnoea</b>		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
<b>Pleural effusion</b>		
subjects affected / exposed	3 / 130 (2.31%)	2 / 130 (1.54%)
occurrences (all)	3	2
<b>Pneumonitis</b>		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
<b>Productive cough</b>		
subjects affected / exposed	3 / 130 (2.31%)	3 / 130 (2.31%)
occurrences (all)	3	3
<b>Pulmonary embolism</b>		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
<b>Rales</b>		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
<b>Respiratory failure</b>		

subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Rhinorrhoea subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	3 / 130 (2.31%) 3	
Sinus congestion subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Wheezing subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Anxiety subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	6 / 130 (4.62%) 6	
Confusional state subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Delirium subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Depressed mood subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Depression subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 2	

Insomnia			
subjects affected / exposed	5 / 130 (3.85%)	6 / 130 (4.62%)	
occurrences (all)	5	6	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	17 / 130 (13.08%)	16 / 130 (12.31%)	
occurrences (all)	26	27	
Amylase increased			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Aspartate aminotransferase increased			
subjects affected / exposed	8 / 130 (6.15%)	11 / 130 (8.46%)	
occurrences (all)	11	14	
Bilirubin conjugated increased			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Blood albumin decreased			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Blood alkaline phosphatase increased			
subjects affected / exposed	4 / 130 (3.08%)	4 / 130 (3.08%)	
occurrences (all)	4	8	
Blood bilirubin increased			
subjects affected / exposed	2 / 130 (1.54%)	1 / 130 (0.77%)	
occurrences (all)	5	8	
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Blood chloride decreased			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Blood creatinine increased			
subjects affected / exposed	5 / 130 (3.85%)	7 / 130 (5.38%)	
occurrences (all)	7	12	
Blood glucose increased			

subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Blood lactate dehydrogenase increased		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	2	1
Blood pressure increased		
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)
occurrences (all)	0	2
Blood urea increased		
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)
occurrences (all)	2	2
Body temperature increased		
subjects affected / exposed	3 / 130 (2.31%)	0 / 130 (0.00%)
occurrences (all)	3	0
C-reactive protein increased		
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)
occurrences (all)	3	3
Creatinine renal clearance decreased		
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)
occurrences (all)	2	2
Electrocardiogram QT prolonged		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	1	1
Electrocardiogram T wave abnormal		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Electrocardiogram abnormal		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Gamma-glutamyltransferase increased		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	1	1
Glomerular filtration rate decreased		

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	5	0
Glomerular filtration rate increased		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Heart rate increased		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Lymphocyte count decreased		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	4	0
Neutrophil count decreased		
subjects affected / exposed	3 / 130 (2.31%)	2 / 130 (1.54%)
occurrences (all)	7	2
Pancreatic enzymes increased		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Platelet count decreased		
subjects affected / exposed	5 / 130 (3.85%)	1 / 130 (0.77%)
occurrences (all)	5	1
Platelet count increased		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Protein total decreased		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Transaminases increased		
subjects affected / exposed	0 / 130 (0.00%)	3 / 130 (2.31%)
occurrences (all)	0	3
Troponin increased		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Weight decreased		
subjects affected / exposed	13 / 130 (10.00%)	7 / 130 (5.38%)
occurrences (all)	13	7
White blood cell count decreased		

subjects affected / exposed occurrences (all)	5 / 130 (3.85%) 7	1 / 130 (0.77%) 1	
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Excoriation subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	1 / 130 (0.77%) 1	
Injury, poisoning and procedural complications			
Back injury subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Contusion subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Fall subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	3 / 130 (2.31%) 3	
Foot fracture subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 2	
Laceration subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Radiation fibrosis subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Skin wound subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Thermal burn			

subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Wrist fracture subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Congenital, familial and genetic disorders Pyloric stenosis subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 2	
Cardiac disorders Angina pectoris subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Arrhythmia subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Atrial fibrillation subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	3 / 130 (2.31%) 3	
Atrial flutter subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Bradycardia subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Cardiac failure subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Cardiomegaly subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Cardiovascular disorder subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Coronary artery disease			

subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Mitral valve incompetence subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	2 / 130 (1.54%) 3	
Tachycardia subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	1 / 130 (0.77%) 1	
<b>Nervous system disorders</b>			
Ageusia subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Aphonia subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	0 / 130 (0.00%) 0	
Ataxia subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 3	
Cerebrovascular accident subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Depressed level of consciousness subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	0 / 130 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	8 / 130 (6.15%) 9	13 / 130 (10.00%) 22	
Dysarthria subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Dysgeusia subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	4 / 130 (3.08%) 4	

Headache		
subjects affected / exposed	11 / 130 (8.46%)	16 / 130 (12.31%)
occurrences (all)	12	20
Hemiparesis		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Hypoaesthesia		
subjects affected / exposed	2 / 130 (1.54%)	1 / 130 (0.77%)
occurrences (all)	2	1
Intracranial pressure increased		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Multiple sclerosis relapse		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Myoclonus		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Neuropathy peripheral		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Paraesthesia		
subjects affected / exposed	8 / 130 (6.15%)	7 / 130 (5.38%)
occurrences (all)	13	16
Peripheral sensory neuropathy		
subjects affected / exposed	4 / 130 (3.08%)	3 / 130 (2.31%)
occurrences (all)	4	7
Polyneuropathy		
subjects affected / exposed	2 / 130 (1.54%)	3 / 130 (2.31%)
occurrences (all)	2	3
Sciatica		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Sinus headache		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0

Somnolence			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	4	0	
Syncope			
subjects affected / exposed	0 / 130 (0.00%)	3 / 130 (2.31%)	
occurrences (all)	0	3	
Tremor			
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)	
occurrences (all)	0	2	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	50 / 130 (38.46%)	40 / 130 (30.77%)	
occurrences (all)	80	56	
Leukocytosis			
subjects affected / exposed	3 / 130 (2.31%)	5 / 130 (3.85%)	
occurrences (all)	3	12	
Leukopenia			
subjects affected / exposed	13 / 130 (10.00%)	8 / 130 (6.15%)	
occurrences (all)	29	31	
Lymphadenopathy			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	1	1	
Lymphopenia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Neutropenia			
subjects affected / exposed	30 / 130 (23.08%)	24 / 130 (18.46%)	
occurrences (all)	83	70	
Pancytopenia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Thrombocytopenia			
subjects affected / exposed	25 / 130 (19.23%)	10 / 130 (7.69%)	
occurrences (all)	47	19	
Thrombocytosis			

subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	2 / 130 (1.54%) 2	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)	
occurrences (all)	2	0	
Tinnitus			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Vertigo			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Dry eye			
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)	
occurrences (all)	2	0	
Eye inflammation			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	1	1	
Eye irritation			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	2	1	
Eye pain			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Eye pruritus			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Eyelid oedema			
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)	
occurrences (all)	1	1	
Foreign body sensation in eyes			

subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Lacrimation increased subjects affected / exposed occurrences (all)	6 / 130 (4.62%) 7	3 / 130 (2.31%) 5	
Macular fibrosis subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Optic atrophy subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Periorbital oedema subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Retinal vein occlusion subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Vision blurred subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	2 / 130 (1.54%) 2	
<b>Gastrointestinal disorders</b>			
Abdominal discomfort subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 3	0 / 130 (0.00%) 0	
Abdominal hernia subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Abdominal pain subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	2 / 130 (1.54%) 2	
Abdominal pain lower subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Abdominal pain upper subjects affected / exposed occurrences (all)	6 / 130 (4.62%) 6	7 / 130 (5.38%) 8	

Abdominal tenderness		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Aerophagia		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Anal fissure		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Anal inflammation		
subjects affected / exposed	4 / 130 (3.08%)	0 / 130 (0.00%)
occurrences (all)	5	0
Anal pruritus		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Anorectal discomfort		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Breath odour		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Cheilitis		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Constipation		
subjects affected / exposed	16 / 130 (12.31%)	7 / 130 (5.38%)
occurrences (all)	22	7
Defaecation urgency		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Dental caries		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Diarrhoea		
subjects affected / exposed	23 / 130 (17.69%)	16 / 130 (12.31%)
occurrences (all)	43	24

Diverticulum		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Dry mouth		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Duodenitis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Dyspepsia		
subjects affected / exposed	2 / 130 (1.54%)	3 / 130 (2.31%)
occurrences (all)	2	3
Dysphagia		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Faeces discoloured		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	3	0
Gastritis erosive		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Gastrooesophageal reflux disease		
subjects affected / exposed	4 / 130 (3.08%)	1 / 130 (0.77%)
occurrences (all)	4	1
Gingival bleeding		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Haematochezia		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Haemorrhoids		
subjects affected / exposed	4 / 130 (3.08%)	0 / 130 (0.00%)
occurrences (all)	4	0

Inguinal hernia		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Large intestinal haemorrhage		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Lip erosion		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Nausea		
subjects affected / exposed	40 / 130 (30.77%)	37 / 130 (28.46%)
occurrences (all)	76	79
Odynophagia		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Oesophagitis		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Oral dysaesthesia		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Oral pain		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	1	1
Perianal erythema		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Proctalgia		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	3	0
Proctitis		
subjects affected / exposed	4 / 130 (3.08%)	0 / 130 (0.00%)
occurrences (all)	4	0
Rectal haemorrhage		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0

Saliva altered subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Stomatitis subjects affected / exposed occurrences (all)	24 / 130 (18.46%) 45	18 / 130 (13.85%) 26	
Toothache subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Vomiting subjects affected / exposed occurrences (all)	25 / 130 (19.23%) 34	17 / 130 (13.08%) 20	
Hepatobiliary disorders Biliary dilatation subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Hepatic cyst subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
Hepatic pain subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Hepatotoxicity subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	1 / 130 (0.77%) 7	
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	4 / 130 (3.08%) 23	
Liver injury subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Alopecia			

subjects affected / exposed	5 / 130 (3.85%)	0 / 130 (0.00%)
occurrences (all)	5	0
Blister		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Chloasma		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Dermatitis		
subjects affected / exposed	6 / 130 (4.62%)	2 / 130 (1.54%)
occurrences (all)	6	2
Dermatitis bullous		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	2	0
Dermatitis contact		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Dry skin		
subjects affected / exposed	9 / 130 (6.92%)	4 / 130 (3.08%)
occurrences (all)	9	4
Ecchymosis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Erythema		
subjects affected / exposed	2 / 130 (1.54%)	4 / 130 (3.08%)
occurrences (all)	3	5
Erythema multiforme		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Hyperhidrosis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Intertrigo		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Nail disorder		

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Night sweats		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	2
Onycholysis		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Palmar-plantar erythrodysesthesia syndrome		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Pruritus		
subjects affected / exposed	4 / 130 (3.08%)	4 / 130 (3.08%)
occurrences (all)	4	4
Purpura		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Rash		
subjects affected / exposed	10 / 130 (7.69%)	8 / 130 (6.15%)
occurrences (all)	12	11
Rash erythematous		
subjects affected / exposed	4 / 130 (3.08%)	3 / 130 (2.31%)
occurrences (all)	9	3
Rash macular		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	2	0
Rash maculo-papular		
subjects affected / exposed	1 / 130 (0.77%)	3 / 130 (2.31%)
occurrences (all)	1	7
Rash papular		
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)
occurrences (all)	0	2
Rash pruritic		
subjects affected / exposed	3 / 130 (2.31%)	2 / 130 (1.54%)
occurrences (all)	3	2

Rash vesicular		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Scar pain		
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)
occurrences (all)	0	2
Skin discolouration		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Skin disorder		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	2
Skin exfoliation		
subjects affected / exposed	1 / 130 (0.77%)	3 / 130 (2.31%)
occurrences (all)	2	3
Skin hyperpigmentation		
subjects affected / exposed	8 / 130 (6.15%)	2 / 130 (1.54%)
occurrences (all)	10	2
Skin irritation		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Skin reaction		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Skin toxicity		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Skin ulcer		
subjects affected / exposed	6 / 130 (4.62%)	0 / 130 (0.00%)
occurrences (all)	6	0
Stasis dermatitis		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Vasculitic rash		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1

Renal and urinary disorders			
Chromaturia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Dysuria			
subjects affected / exposed	5 / 130 (3.85%)	0 / 130 (0.00%)	
occurrences (all)	5	0	
Haematuria			
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)	
occurrences (all)	0	2	
Nephrolithiasis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Nephropathy			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Proteinuria			
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)	
occurrences (all)	0	2	
Renal cyst			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Renal failure			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Renal failure acute			
subjects affected / exposed	0 / 130 (0.00%)	2 / 130 (1.54%)	
occurrences (all)	0	2	
Renal impairment			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Urethral discharge			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			

Arthralgia		
subjects affected / exposed	3 / 130 (2.31%)	7 / 130 (5.38%)
occurrences (all)	3	7
Arthritis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Back pain		
subjects affected / exposed	6 / 130 (4.62%)	16 / 130 (12.31%)
occurrences (all)	8	16
Bone pain		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Coccydynia		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Groin pain		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	2
Intervertebral disc protrusion		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Mobility decreased		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Muscle spasms		
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)
occurrences (all)	1	2
Muscular weakness		
subjects affected / exposed	1 / 130 (0.77%)	1 / 130 (0.77%)
occurrences (all)	1	2
Musculoskeletal chest pain		
subjects affected / exposed	4 / 130 (3.08%)	2 / 130 (1.54%)
occurrences (all)	4	2
Musculoskeletal pain		
subjects affected / exposed	0 / 130 (0.00%)	5 / 130 (3.85%)
occurrences (all)	0	6

Musculoskeletal stiffness			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Myalgia			
subjects affected / exposed	7 / 130 (5.38%)	3 / 130 (2.31%)	
occurrences (all)	13	3	
Neck pain			
subjects affected / exposed	2 / 130 (1.54%)	4 / 130 (3.08%)	
occurrences (all)	2	5	
Osteoarthritis			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Osteochondrosis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Pain in extremity			
subjects affected / exposed	8 / 130 (6.15%)	3 / 130 (2.31%)	
occurrences (all)	15	3	
Sacroiliitis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Spinal pain			
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	4 / 130 (3.08%)	5 / 130 (3.85%)	
occurrences (all)	4	7	
Bronchopneumonia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Cellulitis			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	3	
Conjunctivitis			

subjects affected / exposed	4 / 130 (3.08%)	2 / 130 (1.54%)
occurrences (all)	5	2
Cystitis		
subjects affected / exposed	2 / 130 (1.54%)	1 / 130 (0.77%)
occurrences (all)	2	1
Ear infection		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	2	0
Erysipelas		
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)
occurrences (all)	1	3
Folliculitis		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Furuncle		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	2	0
Gastric infection		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Nasopharyngitis		
subjects affected / exposed	1 / 130 (0.77%)	3 / 130 (2.31%)
occurrences (all)	1	3
Oral candidiasis		
subjects affected / exposed	2 / 130 (1.54%)	2 / 130 (1.54%)
occurrences (all)	2	2
Oral herpes		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Pharyngitis		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Pneumonia		
subjects affected / exposed	4 / 130 (3.08%)	2 / 130 (1.54%)
occurrences (all)	4	2
Pyoderma		

subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Rash pustular		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Respiratory tract infection		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Rhinitis		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Skin infection		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Soft tissue infection		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Subcutaneous abscess		
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)
occurrences (all)	0	1
Tonsillitis		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Upper respiratory tract infection		
subjects affected / exposed	1 / 130 (0.77%)	2 / 130 (1.54%)
occurrences (all)	1	2
Urethritis		
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)
occurrences (all)	2	0
Urinary tract infection		
subjects affected / exposed	4 / 130 (3.08%)	4 / 130 (3.08%)
occurrences (all)	4	4
Vaginal infection		
subjects affected / exposed	1 / 130 (0.77%)	0 / 130 (0.00%)
occurrences (all)	1	0
Viral infection		

subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	2 / 130 (1.54%) 3	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Vulvitis subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 4	0 / 130 (0.00%) 0	
Vulvovaginitis subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	0 / 130 (0.00%) 0	
<b>Metabolism and nutrition disorders</b>			
Decreased appetite subjects affected / exposed occurrences (all)	17 / 130 (13.08%) 27	20 / 130 (15.38%) 27	
Dehydration subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 2	3 / 130 (2.31%) 3	
Diabetes mellitus subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Gout subjects affected / exposed occurrences (all)	0 / 130 (0.00%) 0	1 / 130 (0.77%) 1	
Hyperglycaemia subjects affected / exposed occurrences (all)	4 / 130 (3.08%) 7	11 / 130 (8.46%) 20	
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 130 (0.77%) 1	1 / 130 (0.77%) 1	
Hypoalbuminaemia subjects affected / exposed occurrences (all)	3 / 130 (2.31%) 3	5 / 130 (3.85%) 5	
Hypocalcaemia subjects affected / exposed occurrences (all)	2 / 130 (1.54%) 3	2 / 130 (1.54%) 2	

Hypokalaemia			
subjects affected / exposed	1 / 130 (0.77%)	6 / 130 (4.62%)	
occurrences (all)	1	9	
Hypomagnesaemia			
subjects affected / exposed	3 / 130 (2.31%)	5 / 130 (3.85%)	
occurrences (all)	3	7	
Hyponatraemia			
subjects affected / exposed	2 / 130 (1.54%)	7 / 130 (5.38%)	
occurrences (all)	2	8	
Hypophosphataemia			
subjects affected / exposed	0 / 130 (0.00%)	1 / 130 (0.77%)	
occurrences (all)	0	1	
Hypoproteinaemia			
subjects affected / exposed	2 / 130 (1.54%)	0 / 130 (0.00%)	
occurrences (all)	3	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 September 2014	The primary purposes of Protocol Amendment 1 were to: 1. Add an inclusion criterion requiring testing for EGFR-activating mutations and ALK rearrangement and, if positive, to require appropriate tyrosine kinase inhibitor therapy prior to enrollment 2. Amend the inclusion criterion for adequate hematologic function as measured by hemoglobin from 10 g/dL to 8 g/dL 3. Amend the contraception inclusion criterion to allow implementation of institutional standards for contraception 4. Correct the recommendations regarding use of concomitant anti-inflammatory drugs to accurately reflect pemetrexed labelling 5. Correct the stratification factor regarding extent of disease from M1a vs. M1b to M0/M1a vs M1b 6. Addition of Exclusion Criterion #19 (Section 4.2 Exclusion Criteria) to exclude patients who are concurrently participating in another clinical trial or study 7. To amend the exclusion criterion regarding eligibility of patients with prior additional cancers

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

TH-CR-415 study enrolment ended prematurely in December 2015 due to a futility analysis which determined efficacy threshold would likely not be met. The last study visit occurred on 15April2016, and the database locked in May, 2016.

Notes: